CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received.

Business Wire • 8 hours ago

Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

Zacks Investment Research • a day ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, ​supporting regulatory filings for what could become the first ‌regimen of its kind for the disease.

Reuters • Jul 21, 2026

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2026 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one.

Business Wire • Jul 21, 2026

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. The data to be presented, together with Gilead-led symposia and community forums,.

Business Wire • Jul 21, 2026

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacap.

Business Wire • Jul 21, 2026

Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Investors Business Daily • Jul 17, 2026

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.

Zacks Investment Research • Jul 17, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Jul 16, 2026

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.

24/7 Wall Street • Jul 15, 2026